Should I consider Ipsen?

Discussion in 'Ipsen' started by anonymous, Aug 18, 2019 at 10:44 AM.

Tags: Add Tags
?

Should I consider Ipsen?

  1. yes

    0 vote(s)
    0.0%
  2. RUN!

    0 vote(s)
    0.0%
  1. anonymous

    anonymous Guest

    Ipsen is a constantly changing company which is good and bad.

    IC is a huge issue and numbers are unreliable. There are many divisions of Ipsen that get by doing absolutely nothing.

    in the field contracts are more important than performance, your success can be in someone else’s hands too often.

    the good part is the work life balance, with very few exceptions you won’t be hounded about your numbers.

    Ipsen is a flawed company that knows it’s flawed, it’s a bit of an unspoken agreement.
     

  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    You are describing big pharma basically. Seriously.
     
  4. anonymous

    anonymous Guest

    big pharma indeed, just like goal setting. Some areas have great managed care access yet are asked to grow the exact same amount as a challenging area. One size fits all. Just a reflection of the people who are in IC are braindead and wonder why the company can't keep people very long.
     
  5. anonymous

    anonymous Guest

    You should consider...good people all the way around.
     
  6. anonymous

    anonymous Guest

    If you come here I hope your experience is better than my own and others I know within Ipsen. So far I've witnessed a high level of disregard for patient care and it all being about money vs helping people suffering from some devastating conditions. In about 2 years most people here see the cracks in the foundation and start their exit plan. It's a job and count it as such. This company gets in its own way of being successful.
     
  7. anonymous

    anonymous Guest


    How so? This hasn’t been my experience beyond stupid pricing.

    Ipsen is very engaged with patient communities. If there is an issue it’s that Medical Affairs isn’t as involved as it should be.
     
  8. anonymous

    anonymous Guest

    No
     
  9. anonymous

    anonymous Guest

    management is overbearing here. That’s one reason why there is so much turnover. People are miserable. The only good thing is so many people are getting new jobs and double dipping before giving there resignation, so cashing in some money during covid=19.
     
  10. anonymous

    anonymous Guest

    IC is minimal at best. They do hire people close to retirement, so not bad if you just want another year or 3 for a paycheck. Drug is a joke and the people here will make your life miserable
     
  11. anonymous

    anonymous Guest

    Ipsen is a shell of what it was and rapidly becoming a sewer of failure. It's one misstep and lack of vision after the other for past couple years. This is not the oncology company I signed up for and never will be. Lots of promises made - few kept in clinical development.
     
  12. anonymous

    anonymous Guest

    Neuro is beyond awful. New VP knows nothing. Treats reps like little kids. Continues to make bad decisions. Everyone is miserable here!! RUN.
     
  13. anonymous

    anonymous Guest

    When all the best science minds are ejecting from the Oncology Space- you know the future is not good here at IPSEN. Trials are garbage and future is trash. Run!
     
  14. anonymous

    anonymous Guest

    I completely disagree about the new VP in Neuro. My experience is that she has been standing up for her people and works tirelessly to create an positive, open and collaborative culture. Things are changing, as it should with a new VP, but I believe her intentions are good. If you think Neuro is awful, you really don't know the hard working people I know - you may want to look in the mirror because you will likely find what has made it awful for you. I wish you luck and much happiness - somewhere else.
     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    You got a new indication today. Do you still feel this way?
     
  18. anonymous

    anonymous Guest

     
  19. anonymous

    anonymous Guest

    Oncology drugs not going anywhere fast. One will have several generic versions in next year or two, and the other will probably not move up the line in treatment sequencing anytime soon. Some management very good, and on the other hand some is not very good at all. Heard mid-south manager still thinks it's 1999 Pfizer days, and no accountability for his 'management' style.
     
  20. anonymous

    anonymous Guest

    With Brad leaving and a new CEO, you can bet things will get real interesting